ArticleFrontiers in cellular and infection microbiology2026
Machine learning-based prediction of bloodstream infection in rectal carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: We included patients with first-time positive rectal CRE surveillance cultures during hospitalization at three hospitals in Korea from January 2014 to December 2023. A total of 173 features-laboratory data including the carbapenem minimum inhibitory concentrations (MIC) of rectal CRE isolates and complete blood cell count, demographics, vital signs, comorbidities, medications, transfusions, and procedures -were collected for the 30-day and 14-day follow-up periods, of which 151 remained after removing redundant features. The entire dataset was randomly split into training (80%) and test (20%) sets, and XGBoost ML models were developed. Model performance was evaluated using the area under the receiver operator characteristic curve (AUROC) with 1, 000 bootstrap iterations. SHAP (SHapley Additive exPlanations) was employed as the XAI method. Results: Among 639 included CRE carriers, 72 (11.3%) and 46 (7.2%) developed BSI within 30 and 14 days, respectively. The 30-day and 14-day models demonstrated excellent performance with AUROCs of 0.917 (95% CI: 0.889-0.943) and 0.854 (95% CI: 0.821-0.885), respectively. In the 30-day model, the most contributory feature was minimum inhibitory concentration (MIC) of imipenem or meropenem against rectal CRE, with BSI risk increasing when MIC ≥8 μg/mL. In the 14-day model, increased neutrophil count (≥7.50×10³/μL) was the most contributory feature. Several features showed nonlinear relationships with BSI risk and contrasting contributions depending on feature interactions. Individual 30-day and 14-day prediction models required at least 12 top-contributing features, achieving AUROCs of 0.873 (95% CI: 0.728-0.969) and 0.864 (95% CI: 0.727-0.959), respectively. Conclusions: The influence of contributing features varied by time periods and interactions. This study comprehensively interpreted complex factors using ML and XAI, achieving excellent predictive performance. Individualized BSI risk stratification can facilitate determining appropriate timing for preemptive therapy and inform antimicrobial stewardship decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.